{"id":42099,"date":"2025-09-23T15:40:13","date_gmt":"2025-09-23T07:40:13","guid":{"rendered":"https:\/\/flcube.com\/?p=42099"},"modified":"2025-09-23T15:40:14","modified_gmt":"2025-09-23T07:40:14","slug":"eisai-secures-fda-fast-track-for-etalanetug-a-tau-antibody-targeting-mtbr","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42099","title":{"rendered":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR"},"content":{"rendered":"\n<p><strong>Eisai Co. Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>)<\/strong> announced today that its investigational tau\u2011protein antibody <strong>etalanetug (E2814)<\/strong> has been granted <strong>Fast Track designation<\/strong> by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-features-of-etalanetug\">Key Features of Etalanetug<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Tau Seeding<\/strong> \u2013 Etalanetug selectively binds tau protein \u201cseeds\u201d containing the MTBR, the critical region responsible for propagating tau aggregates to vulnerable brain regions.<\/li>\n\n\n\n<li><strong>Collaborative Development<\/strong> \u2013 The antibody is the product of a partnership between <strong>Eisai<\/strong> and <strong>University College London<\/strong>, combining pharmaceutical expertise with cutting\u2011edge neurobiological research.<\/li>\n\n\n\n<li><strong>Fast Track Implications<\/strong> \u2013 With Fast Track status, Eisai is positioned to benefit from accelerated FDA review, priority interaction, and potential priority review status if the drug meets the criteria for clinical benefit.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alzheimer\u2019s &amp; Tau\u2011Related Disorders<\/strong> \u2013 Tau pathology underlies a spectrum of neurodegenerative diseases, including Alzheimer\u2019s disease and frontotemporal dementia. Etalanetug\u2019s targeted approach represents a novel therapeutic strategy distinct from amyloid\u2011focused agents.<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong> \u2013 The Fast Track designation enhances Eisai\u2019s emerging tau therapy portfolio, complementing its existing Alzheimer\u2019s drug candidates and positioning the company as a leader in disease\u2011modifying treatments.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong> \u2013 The FDA\u2019s expedited pathway underscores the agency\u2019s commitment to addressing unmet needs in neurodegeneration and signals strong regulatory interest in tau\u2011targeted therapies.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[350,1151],"class_list":["post-42099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eisai","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42099\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR\" \/>\n<meta property=\"og:description\" content=\"Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42099\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T07:40:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T07:40:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR\",\"datePublished\":\"2025-09-23T07:40:13+00:00\",\"dateModified\":\"2025-09-23T07:40:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099\"},\"wordCount\":256,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2309.webp\",\"keywords\":[\"Eisai\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42099#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42099\",\"name\":\"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2309.webp\",\"datePublished\":\"2025-09-23T07:40:13+00:00\",\"dateModified\":\"2025-09-23T07:40:14+00:00\",\"description\":\"Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42099\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2309.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2309.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42099#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR - Insight, China&#039;s Pharmaceutical Industry","description":"Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42099","og_locale":"en_US","og_type":"article","og_title":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR","og_description":"Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.","og_url":"https:\/\/flcube.com\/?p=42099","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-23T07:40:13+00:00","article_modified_time":"2025-09-23T07:40:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42099#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42099"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR","datePublished":"2025-09-23T07:40:13+00:00","dateModified":"2025-09-23T07:40:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42099"},"wordCount":256,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42099#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp","keywords":["Eisai","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42099#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42099","url":"https:\/\/flcube.com\/?p=42099","name":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42099#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42099#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp","datePublished":"2025-09-23T07:40:13+00:00","dateModified":"2025-09-23T07:40:14+00:00","description":"Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau\u2011protein antibody etalanetug (E2814) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation, aimed at expediting the development of drugs that address unmet medical needs, follows the antibody\u2019s focus on microtubule\u2011binding region (MTBR) tau subtypes that drive the spread of tau pathology across the brain.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42099#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42099"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42099#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp","width":1080,"height":608,"caption":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42099#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2309.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42099"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42099\/revisions"}],"predecessor-version":[{"id":42103,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42099\/revisions\/42103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42102"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}